Abbvie and Genentech Announce Official Launch on TrumpRx Platform
American pharmaceutical giants Abbvie and Genentech have announced their official launch on the TrumpRx platform. This marks a significant step in providing discounted medications via the White House’s pharmaceutical site. The two companies become the 10th and 11th contributors to this discounted service.
Discounted Medications from Abbvie and Genentech
Abbvie will be offering its well-known medication, Humira, on the TrumpRx platform. Humira is commonly prescribed for rheumatoid arthritis, Crohn’s disease, and ulcerative colitis. The significant news is that this medication will be available at an 86% discount.
Availability and Pricing
- Discounted price for Humira: $950
- Original list price: Over $6,900 for uninsured patients
This discount is aimed specifically at uninsured individuals or those whose insurance does not cover the medication. Patients typically paying full price may see substantial savings through the TrumpRx platform. However, those already insured often receive lower prices through their plans.
Future Plans and Legislative Context
A White House official indicated plans to formalize these discount agreements within the “Great Healthcare Plan.” This would allow patients on government insurance to utilize copays for medications available on TrumpRx. Currently, Congress has not progressed legislation associated with this initiative.
Genentech’s Offerings
Genentech is also joining TrumpRx with its single-dose flu treatment, Xofluza. The price for this medication is set at around $50, reduced from its original cost of $168.
Expansion of TrumpRx
Alongside Abbvie and Genentech, Amgen is expected to expand its offerings on TrumpRx. The company plans to include the arthritis medication Enbrel and the psoriasis treatment Otezla. As of now, TrumpRx features over 61 medications available at reduced prices, up from approximately 40 when the site was launched in February.
The Trump administration emphasizes lowering prescription drug prices for uninsured consumers through “most-favored-nation” agreements. This policy aims to ensure that U.S. consumers benefit from prices that are comparable to those offered in other countries.
